Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Neuropharmacology

• Publication date

  2012-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neuropharm.2012.06.011PMID 22722025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat--response to pharmacological modulation.

  2012cited by this paper
• Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates.

  2011cited by this paper
• Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio

  2011cited by this paper
• Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.

  2011cited by this paper
• Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.

  2011cited by this paper
• MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.

  2010cited by this paper
• Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease

  2010cited by this paper
• Dopamine D1, D2 and mu-opioid receptors are co-expressed with adenylyl cyclase 5 and phosphodiesterase 7B mRNAs in striatal rat cells.

  2010cited by this paper
• Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

  2010cited by this paper
• A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.

  2010cited by this paper
• Understanding graft-induced dyskinesia.

  2010influential reference
• Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.

  2010cited by this paper
• Thalamic Deep Brain Stimulation for Writer's Cramp.

  2009cited by this paper
• Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease

  2009cited by this paper
• Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study

  2009cited by this paper
• Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats

  2009cited by this paper
• Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

  2009cited by this paper
• Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.

  2009cited by this paper
• Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease.

  2008cited by this paper
• Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6‐OHDA lesioned rat

  2008cited by this paper
• Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON l-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease

  2008cited by this paper
• Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

  2008cited by this paper
• Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias

  2008cited by this paper
• Non-dopaminergic treatments in development for Parkinson's disease.

  2008cited by this paper
• Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.

  2008cited by this paper
• Deep brain stimulation in Parkinson's disease following fetal nigral transplantation

  2008cited by this paper
• Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.

  2007cited by this paper
• Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease.

  2007influential reference
• Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons.

  2007cited by this paper
• Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice

  2007cited by this paper
• D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons.

  2007cited by this paper
• Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.

  2007cited by this paper
• Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

  2007cited by this paper
• Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease

  2007cited by this paper
• An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections.

  2006cited by this paper
• The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.

  2006cited by this paper
• Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats.

  2006cited by this paper
• Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.

  2006cited by this paper
• Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.

  2005cited by this paper
• Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

  2005cited by this paper
• Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia

  2005cited by this paper
• Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

  2005cited by this paper
• Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

  2005cited by this paper
• Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain

  2004cited by this paper
• Amphetamine, apomorphine and investigatory behavior in the rat: Analysis of the structure and pattern of responses

  2004cited by this paper
• Real‐time decoding of dopamine concentration changes in the caudate–putamen during tonic and phasic firing

  2004cited by this paper
• Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease

  2004cited by this paper
• Preoperative response to levodopa is the best predictor of transplant outcome

  2004cited by this paper
• DAncing past the DAT at a DA synapse.

  2004cited by this paper
• Embryonic mesencephalic grafts increase levodopa‐induced forelimb hyperkinesia in parkinsonian rats

  2003cited by this paper
• A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

  2003cited by this paper
• Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkinson model.

  2003cited by this paper
• Book Review: Cellular Replacement Therapy for Parkinson’s Disease—Where We Are Today?

  2002cited by this paper
• Cellular replacement therapy for Parkinson's disease--where we are today?

  2002cited by this paper
• L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

  2002cited by this paper
• Dyskinesias following neural transplantation in Parkinson's disease

  2002cited by this paper
• Dyskinesia after fetal cell transplantation for parkinsonism: A PET study

  2002cited by this paper
• Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

  2002cited by this paper
• SUBSTANTIA N I G R A IN RATS SUBJECTED TO 6-OHDA LESIONS OF THE N I G R O S T R I A T A L PATHWAY. I. U N I L A T E R A L LESIONS

  2002cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

  2001cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease

  2001cited by this paper
• Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

  2001cited by this paper
• High dose naltrexone for dyskinesias induced by levodopa

  2001cited by this paper
• Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease

  2001cited by this paper
• Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.

  2000cited by this paper
• Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

  1999cited by this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cited by this paper
• Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization.

  1996cited by this paper
• Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.

  1996cited by this paper
• Effects of selective activation of the 5-HT1B receptor with CP-94,253 on sleep and wakefulness in the rat.

  1995cited by this paper
• Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease

  1995cited by this paper
• Bilateral Motor Improvement and Alteration of L-dopa Effect in Two Patients With Parkinsonʼs Disease Following Intrastriatal Transplantation of Foetal Ventral Mesencephalon

  1995cited by this paper
• Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon.

  1994cited by this paper
• Transplantation of fetal mesencephalic tissue in Parkinson's patients.

  1994cited by this paper
• Buspirone in levodopa-induced dyskinesias.

  1994cited by this paper
• Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients.

  1993cited by this paper
• Dopamine-rich grafts in the neostriatum and/or nucleus accumbens: effects on drug-induced behaviours and skilled paw-reaching.

  1993cited by this paper
• Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up.

  1989cited by this paper
• Distribution of dopamine D1 and D2 receptors in rabbit cortical areas, hippocampus, and neostriatum in relation to dopamine contents

  1989cited by this paper
• The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting

  1986cited by this paper
• Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions.

  1981cited by this paper
• Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.

  1979cited by this paper
• Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway.

  1976cited by this paper
• Combined treatment of parkinsonism with L-dopa and amantadine.

  1970cited by this paper
• Combined treatment of parkinsonism with L-dopa and amantadine.

  1970cited by this paper
• Estimation of nuclear population from microtome sections

  1946cited by this paper

• Evaluation of the potential therapeutic effect of africanized honeybee venom (Apis mellifera Linnaeus) on levodopa-induced dyskinesias in mice.

  2025cites this paper
• Advancing age and the rs6265 BDNF SNP are permissive to graft-induced dyskinesias in parkinsonian rats

  2024cites this paper
• Advancing Age and the rs6265 BDNF SNP are Permissive to Graft-induced Dyskinesias in Parkinsonian Rats

  2024cites this paper
• Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia

  2022cites this paper
• L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease

  2021cites this paper
• Serotonin 1A receptor agonist modulation of motor deficits and cortical oscillations by NMDA receptor interaction in parkinsonian rats.

  2021cites this paper
• The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats

  2020cites this paper
• Methamphetamine persistently increases alpha-synuclein and suppresses gene promoter methylation within striatal neurons.

  2019cites this paper
• Cannabis for Basal Ganglia Disorders (Parkinson Disease and Huntington Disease)

  2017cites this paper
• 5-Hydroxy-tryptamine (5HT)-Related Therapy in Neurological Diseases

  2016cites this paper
• Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

  2016cites this paper
• Monoamine Reuptake Inhibitors in Parkinson's Disease

  2015cites this paper
• Mutual influence of serotonin and dopamine on the functioning of the dorsal striatum and motor activity (hypothetical mechanism)

  2014cites this paper
• Transplantation of Melanocytes Obtained from the Skin Ameliorates Apomorphine-Induced Abnormal Behavior in Rodent Hemi-Parkinsonian Models

  2013cites this paper
• Endogenous opiates and behavior: 2012.

  2013cites this paper
• Two cells are better than one: optimizing stem cell survival by co-grafting "helper" cells that offer regulated trophic support.

  2013cites this paper
• Parameters impacting the outcome of cellreplacement therapy for Parkinson’s disease:A preclinical study

  2013cites this paper
• Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.

  2013cites this paper
• l-DOPA and graft-induced dyskinesia: Different treatment, same story?

  2013cites this paper
• Assessment of Therapeutic Potential of Amantadine in Methamphetamine Induced Neurotoxicity

  2013cites this paper
• L-DOPA- and graft-induced dyskinesia following transplantation.

  2012cites this paper